Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Primary progressive multiple sclerosis: part of the MS disease spectrum or separate disease entity?
FDA Approves First Drug for Lou Gehrig's Disease
Regulation of encephalitogenicity of neuroantigen-primed T cells by nitric oxide: Implications for multiple sclerosis.
CD44 is required for the migration of transplanted oligodendrocyte progenitor cells to focal inflammatory demyelinating lesions in the spinal cord.
Expansion of oligodendrocyte progenitor cells following SIRT1 inactivation in the adult brain.
Rebif Advanced Magnetic Resonance Imaging (MRI) and Immunology Pilot Trial
Discovery of Tetrahydropyrazolopyridine as Sphingosine 1-Phosphate Receptor 3 (S1P3)-Sparing S1P1 Agonists Active at Low Oral Doses.
Limb Apraxia in Multiple Sclerosis: Prevalence and Impact on Manual Dexterity and Activities of Daily Living.
New technologies for biomarker discovery in multiple sclerosis.
Center for Drug Evaluation and Research Approval Letter, application number: 21-897
Fingolimod for multiple sclerosis: a review for the specialist nurse.
A culture system to study oligodendrocyte myelination processes using engineered nanofibers.
Microglia: Architects of the Developing Nervous System.
Enhanced myelination in autoimmunity and in normal development induced by glatiramer acetate.
Pharmacodynamics, pharmacokinetics, and safety of multiple doses of FTY720 in stable renal transplant patients: a multicenter, randomized, placebo-controlled, phase I study.
The role of Acinetobacter in the pathogenesis of multiple sclerosis examined by using Popper sequences.
[Damage of macular ganglion cell complex and peripapillary retinal nerve fiber layer in multiple sclerosis.]
Biomarkers for multiple sclerosis.
Substance Name: Riluzole
Cognitive Impairment Has a Strong Relation to Nonsomatic Symptoms of Depression in Relapsing-Remitting Multiple Sclerosis.
Pharmacology of HIV integrase inhibitors.
Nabilone as an Adjunctive to Gabapentin for Multiple Sclerosis-Induced Neuropathic Pain: A Randomized Controlled Trial.
Graves' disease after treatment with Alemtuzumab for multiple sclerosis.
Efficacy and safety of alemtuzumab in patients with relapsing-remitting multiple sclerosis who relapsed on prior therapy: Four-year follow-up of the Care-MS II study.
Individual differences in depression are associated with abnormal function of the limbic system in multiple sclerosis patients.

Pages